

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: CITATION GROWTH CORP. the "Issuer" or "Cgro" or "the Company").

Trading Symbol: CGRO

Number of Outstanding Listed Securities: 61,969,032

Date: July 4, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.
 - (a) On June 4, 2019, the Company provided a corporate update regarding its North Las Vegas operations and proposed acquisition of ACC Group of Companies ("ACC") primarily related to the planned expansion of the Company's North Las Vegas cultivation facility and ACC's Pahump, Nevada licensed facility.
 - (b) On June 10, 2019, the Company announced its change of name from Liht Cannabis Corp. to Citation Growth Corporation and consolidation of its common shares on the basis of one post-consolidation share for every four pre-consolidation common shares, effective June 12, 2019.
 - (c) On June 17, 2019, the Company announced that it has executed a definitive agreement to acquire all of the equity interests of ACC.

Additionally, the Company announced the closing of its second tranche of a non-brokered private placement of secured Convertible Debentures for gross proceeds of \$250,000.
 - (d) On June 26, 2019, the Company announced that is has successfully passed all local building and electrical inspections for its extraction lab and manufacturing kitchen and has been granted a final approval by the State of Nevada to begin operations under the production license held by its wholly-owned subsidiary, EcoNevada LLC.

2. Provide a general overview and discussion of the activities of management.

See Item 1.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See Item 1(c). The acquisition is an arm's length transaction.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None

11. Report on any labour disputes and resolutions of those disputes if applicable.

None

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

No new claims and litigations.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

On June 7, 2019, the Company’s wholly-owned subsidiary, Full Spectrum Medicinal Inc., obtained an additional mortgage loan in the amount of \$125,000. The loan bears interest at 9% per annum and matures on June 7, 2020.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Stock options	300,000	Grant of Options	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None

16. Provide details of any changes in directors, officers or committee members.

None

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

None

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof, there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 4, 2019.

Nilda Rivera
Name of Director or Senior Officer

"Nilda Rivera"
Signature

CFO
Official Capacity

<i>Issuer Details</i> Name of Issuer Citation Growth Corp.	For Month End June 2019	Date of Report YY/MM/D 19/07/04
Issuer Address 102-1561 Sutherland Avenue		
City/Province/Postal Code Kelowna, BC V1Y 5Y7	Issuer Fax No. () N/A	Issuer Telephone No. 1-877-438-5448 ext. 702
Contact Name Nilda Rivera	Contact Position CFO	Contact Telephone No. 1-877-438-5448 ext. 702
Contact Email Address nilda@citationgrowth.com	Web Site Address Kelowna, BC V1Y 5Y7	